MAP2K7 and melanoma: Notably, these trials have reported a marked improvement in recurrence‐free survival (RFS) among melanoma patients treated with high‐dose interferon‐α, immune checkpoint inhibitors (pembrolizumab, nivolumab), and BRAF/MEK inhibitors.1, 2, 3, 4